ASH 2022 | First-in-human study of TG-1801, a CD19/CD47 bispecific antibody ± ublituximab in BCL
Eliza Hawkes, FRACP, MD, MBBS, Austin Health, Melbourne, Australia, outlines the results from a first-in-human study investigating treatment with TG-1801, a CD19/CD47 bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and indolent lymphomas. Dr Hawkes reports the low toxicity of the treatment and the promising efficacy when used in tandem with ublituximab. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Regeneron: Speakers Bureau; Janssen: Speakers Bureau; Astra Zeneca: Speakers Bureau; Merck Sharpe and Dohme: Membership on an entity’s Board of Directors or advisory committees; Roche: Membership on an entity’s Board of Directors or advisory committees; Bristol_Myers Squibb: Membership on an entity’s Board of Directors or advisory committees; Astra Zeneca: Research Funding; Merck KgA: Research Funding; Bristol-Myers Squibb: Research Funding; Roche: Research Funding; Roche: Speakers Bureau; Gilead: Membership on an entity’s Board of Directors or advisory committees; Antengene: Membership on an entity’s Board of Directors or advisory committees; Link: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Beigene: Membership on an entity’s Board of Directors or advisory committees; Specialised Therapeutics: Consultancy.
